Twelve proteins measured in stored blood were tied to prostate cancers diagnosed more than 15 years after the samples were drawn, in an Oxford Population Health study of over 2,500 men. The University of Oxford announced the findings on October 22, once the paper had appeared in European Urology and at the American Society of Human Genetics annual meeting.

Each man gave his sample years before anything was wrong. Long afterward, the protein patterns separated those who went on to develop the disease from those who did not, while a further set of markers picked out the aggressive cases.

A dozen circulating proteins differed more than 15 years ahead of diagnosis, yet no test a doctor could order has been built on them, a point the researchers themselves make.

Oxford Measured 6,000 Proteins In Blood Drawn Years Before Any Diagnosis

The samples came from the European Prospective Investigation into Cancer and Nutrition, a long-running project known as EPIC. Researchers analyzed blood from 982 men who later developed the cancer and from 1,573 men chosen at random, with follow-up lasting around 16 years, as GEN’s report lays out. More than 6,000 proteins were measured in each man’s plasma. Cancer Research UK part-funded the work.

First author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health, put the motivation simply: “Prostate cancer is not one disease.”

One Immune Protein Pointed The Opposite Way

Higher levels of GZMK, a protein made by immune cells that recognize and destroy abnormal cells, went along with a lower risk of cancers diagnosed more than 15 years later. In the team’s reading, immune activity may keep the disease in check long before any doctor finds it.

Huang told Medical News the result stood out because “prostate cancer is generally considered an immunologically ‘cold’ tumour.” A caution belongs beside it: a protein difference years ahead of diagnosis doesn’t prove the cancer was already present when the blood was drawn.

Seven Proteins Followed The Aggressive Cancers

Beyond overall risk, the analysis tracked markers of the dangerous forms of the disease:

  • ANKRD1: tied to a 23% to 29% higher hazard across high-grade, advanced-stage and lethal disease, according to News-Medical’s breakdown.
  • Driver-gene proteins: blood levels of proteins from ERBB3, KRAS and NRAS, genes already known to matter in this cancer, were linked to aggressive cases diagnosed around a decade later.
  • The wider set: seven proteins in all followed aggressive disease, clustering around immunity, cell adhesion and the growth of new blood vessels.

Senior author Karl Smith-Byrne said spotting driver-gene proteins in blood collected years before diagnosis gives new insight into the earliest stages of the disease.

Any Test Built On This Is Years Away

Prabhakar Rajan, a professor at Queen Mary University of London, welcomed the research while keeping its claims in bounds. He told LBC the study “does not yet establish that a protein-based blood test can reliably identify men” headed for aggressive disease. The authors agree that more research must come before any of these proteins serve as a screening tool.

Reasons for patience are easy to list. The work shows associations across a large group. A pattern of that kind says little about any single man’s future. Study volunteers were drawn from European cohorts recruited decades ago, so the patterns need confirming in today’s more varied populations.

Keep The Screening Conversation You Already Have With Your Doctor

Checkups won’t change on the strength of this paper. Risk assessment today rests on age, family history and the PSA blood test, so a man worried about the disease ought to raise those with his doctor as before. Where this research may eventually pay off, in the authors’ view, lies in understanding how aggressive cancers announce themselves early, so that prevention and screening can aim at the right men.

For more on this cancer, see our earlier piece on a new antibody drug that halts aggressive prostate cancer spread. Our report on weak thinking scores in your 60s and stroke risk covers another early warning sign under study.

Leave a comment